Strong implied Q4 to meet raised FY'24 guidance is achievable Clear profitability focus: cutting '24...
Redeye comments on Ngenic’s announcement of a SEK34m rights issue of units consisting of shares and ...
Redeye comments on the outcome of Iconovo’s rights issue.
Obducat AB (publ) (”Obducat” eller ”Bolaget”) levererade stark exekvering under det tredje kvartalet...
Redeye comments on Flexion Mobile's Q3 2024 report, which was better than expected in terms of margi...
Q3 EBIT -94m (ABGSCe SEK -19m) Minor estimate revisions, given Q3 small quarter Fågelås, Boarp, Dåll...
Redeye comments on Asmodee’s CMD which focused on the tabletop market dynamics, the company’s busine...
Redeye comments on Lytix' Q3 report. The main event since our last update is the start of the NeoLIP...
FY'24 ARR guidance lowered to DKK 101m-106m on KYC delays.
Redeye views Xbrane’s announcement of a partner for its Opdivo biosimilar as a positive development ...
Following the end of Q3-24, Pharma Equity Group (“PEG” or “the Company”) secured additional funding ...
Redeye comments on Active Biotech's 2024 rights issue and updates its base case.
Under kvartalet nåddes överenskommelser med majoriteten av obligationsinvesterarna och efter kvartal...
Redeye comments on Embracer's announcment of Asmodee's financial targets and an equity investment of...
Redeye downgrades Nekkar’s outlook on the back of a Q3’24 report that missed our forecast, mainly dr...
